Form 4: Avadel Director Sells Shares After Alkermes Buyout

Naseem Amin, a director at Avadel Pharmaceuticals, disposed of ordinary shares and stock options following the company's acquisition by Alkermes plc.

Summary

• Naseem Amin, a director of Avadel Pharmaceuticals plc, disposed of 22,000 ordinary shares at $21.00 per share.
• The disposition occurred on February 12, 2026, as part of the acquisition of Avadel Pharmaceuticals plc by Alkermes plc.
• Each outstanding ordinary share was converted into $21.00 in cash and a non-transferable contingent value right (CVR) for a potential additional $1.50 per share.
• Restricted Stock Awards vested in full and were treated in the same manner as ordinary shares.
• Stock options were canceled and exchanged for cash equal to the product of the total number of shares subject to such option multiplied by the excess of the Cash Consideration ($21.00) over the applicable exercise price, plus one CVR for each underlying share.
• Amin disposed of options to buy 49,500 shares with an exercise price of $15.94, 11,000 shares with an exercise price of $16.32, and 11,000 shares with an exercise price of $10.83.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive outcome for the reporting person, Naseem Amin, as it represents the successful monetization of his equity and options in Avadel Pharmaceuticals through an acquisition, with potential for additional upside via CVRs.

Positives

• The reporting person received a cash consideration of $21.00 per ordinary share as part of the acquisition.
• There is a potential for an additional $1.50 per share via Contingent Value Rights (CVRs) upon the achievement of certain milestones.
• Restricted Stock Awards vested in full, allowing holders to participate in the acquisition terms.
• Stock options were cashed out, providing immediate value to option holders based on the acquisition price.

Negatives

• Avadel Pharmaceuticals plc is no longer an independent publicly traded entity, having been acquired by Alkermes plc.
• The Contingent Value Rights (CVRs) are non-transferable, which limits liquidity for the potential additional payment.

Risks

• Achievement of the $1.50 per share contingent value right is dependent on certain milestones, introducing uncertainty regarding the full potential payout.

Future Outlook

The filing primarily reports a past transaction (acquisition completion) and the resulting disposition of securities. The only forward-looking aspect is the potential for a $1.50 per share contingent value right payment, which is dependent on future milestone achievement.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects the final stages of a corporate acquisition in the pharmaceutical sector, a common occurrence as larger companies seek to expand portfolios or achieve synergies through strategic buyouts. The use of CVRs is a frequent mechanism in biotech and pharma M&A to bridge valuation gaps and incentivize post-acquisition performance.

Comparison to Industry Standards

• This transaction structure, involving a cash component and a contingent value right (CVR), is a common approach in pharmaceutical and biotechnology acquisitions.
• Similar CVR structures have been observed in deals such as Merck's acquisition of Acceleron Pharma or Novartis's acquisition of The Medicines Company, where additional payments were tied to regulatory approvals or sales milestones.
• The $21.00 cash consideration plus a potential $1.50 CVR per share represents the agreed-upon valuation for Avadel, which would be assessed against comparable transactions in the specialty pharma space based on revenue multiples, pipeline value, and market capitalization at the time of the initial agreement.

Stakeholder Impact

• Shareholders: Received $21.00 cash per share and a CVR for a potential additional $1.50, effectively cashing out their investment in Avadel.
• Option Holders: Received cash for the in-the-money value of their options plus CVRs.
• Employees (with Restricted Stock Awards): Their awards vested fully and were converted into the same consideration as ordinary shares.

Next Steps

• Achievement of milestones for the contingent value rights to trigger the additional $1.50 per share payment.

Key Dates

Keywords

Avadel Pharmaceuticals, Alkermes, SEC Form 4, Beneficial Ownership, Acquisition, Merger, Contingent Value Right, CVR, Stock Option, Ordinary Shares, Naseem Amin, Director, Disposition